Tumor immunogenicity and responsiveness to cancer vaccine therapy: the state of the art.

Autor: Schreiber TH; Departmentof Microbiology and Immunology, University of Miami Leonard Miller School of Medicine, Miami, FL 33101, United States., Raez L, Rosenblatt JD, Podack ER
Jazyk: angličtina
Zdroj: Seminars in immunology [Semin Immunol] 2010 Jun; Vol. 22 (3), pp. 105-12. Date of Electronic Publication: 2010 Mar 11.
DOI: 10.1016/j.smim.2010.02.001
Abstrakt: Despite enormous effort, promising pre-clinical data in animal studies and over 900 clinical trials in the United States, no cancer vaccine has ever been approved for clinical use. Over the past decade a great deal of progress has been in both laboratory and clinical studies defining the interactions between developing tumors and the immune system. The results of these studies provide a rationale that may help explain the failure of recent therapeutic cancer vaccines in terms of vaccine principles, in selecting which tumors are the most appropriate to target and instruct the design and implementation of state-of-the-art cancer vaccines.
(Copyright 2010 Elsevier Ltd. All rights reserved.)
Databáze: MEDLINE
Externí odkaz: